These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 34218785)

  • 21. [Glutamate hypothesis of schizophrenia and targets for new antipsychotic drugs].
    Hashimoto K; Iyo M
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2002 Feb; 22(1):3-13. PubMed ID: 11917507
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glycine transporter-1: a new potential therapeutic target for schizophrenia.
    Hashimoto K
    Curr Pharm Des; 2011; 17(2):112-20. PubMed ID: 21355838
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glutamate and modeling of schizophrenia symptoms: review of our findings: 1990-2014.
    Gargiulo PÁ; Landa De Gargiulo AI
    Pharmacol Rep; 2014 Jun; 66(3):343-52. PubMed ID: 24905508
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis.
    Tsai GE; Lin PY
    Curr Pharm Des; 2010; 16(5):522-37. PubMed ID: 19909229
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The NMDA receptor 'glycine modulatory site' in schizophrenia: D-serine, glycine, and beyond.
    Balu DT; Coyle JT
    Curr Opin Pharmacol; 2015 Feb; 20():109-15. PubMed ID: 25540902
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site.
    Shim SS; Hammonds MD; Kee BS
    Eur Arch Psychiatry Clin Neurosci; 2008 Feb; 258(1):16-27. PubMed ID: 17901997
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of paliperidone and risperidone on extracellular glutamate in the prefrontal cortex of rats exposed to prenatal immune activation or MK-801.
    Roenker NL; Gudelsky G; Ahlbrand R; Bronson SL; Kern JR; Waterman H; Richtand NM
    Neurosci Lett; 2011 Aug; 500(3):167-71. PubMed ID: 21699956
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glutamate signaling in the pathophysiology and therapy of schizophrenia.
    Lin CH; Lane HY; Tsai GE
    Pharmacol Biochem Behav; 2012 Feb; 100(4):665-77. PubMed ID: 21463651
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Schizophrenia: Basic and Clinical.
    Coyle JT
    Adv Neurobiol; 2017; 15():255-280. PubMed ID: 28674984
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intracellular signaling and approaches to the treatment of schizophrenia and associated cognitive impairment.
    Snyder GL; Vanover KE
    Curr Pharm Des; 2014; 20(31):5093-103. PubMed ID: 24345266
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Unmet needs in the treatment of schizophrenia: new targets to help different symptom domains.
    Citrome L
    J Clin Psychiatry; 2014; 75 Suppl 1():21-6. PubMed ID: 24581451
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in the Treatment of Cognitive Impairment in Schizophrenia: Targeting NMDA Receptor Pathways.
    Zhang T; Liu C; Zhong N; Wang Y; Huang Y; Zhang X
    Int J Mol Sci; 2024 Oct; 25(19):. PubMed ID: 39408997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glutamatergic drugs for schizophrenia.
    Tuominen HJ; Tiihonen J; Wahlbeck K
    Cochrane Database Syst Rev; 2006 Apr; 2006(2):CD003730. PubMed ID: 16625590
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of glycine transporter 1: The yellow brick road to new schizophrenia therapy?
    Singer P; Dubroqua S; Yee BK
    Curr Pharm Des; 2015; 21(26):3771-87. PubMed ID: 26205290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Evidence on the key role of the metabotrobic glutamatergic receptors in the pathogenesis of schizophrenia: a "breakthrough" in pharmacological treatment].
    Pannese R; Minichino A; Pignatelli M; Delle Chiaie R; Biondi M; Nicoletti F
    Riv Psichiatr; 2012; 47(2):149-69. PubMed ID: 22622251
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bringing order to the glutamate chaos in schizophrenia.
    Moghaddam B
    Neuron; 2003 Dec; 40(5):881-4. PubMed ID: 14659087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glutamatergic agents for schizophrenia: current evidence and perspectives.
    Zink M; Correll CU
    Expert Rev Clin Pharmacol; 2015 May; 8(3):335-52. PubMed ID: 25916667
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of
    Goh KK; Wu TH; Chen CH; Lu ML
    J Psychopharmacol; 2021 Mar; 35(3):236-252. PubMed ID: 33406959
    [TBL] [Abstract][Full Text] [Related]  

  • 39. N-aryl piperazine metabotropic glutamate receptor 5 positive allosteric modulators possess efficacy in preclinical models of NMDA hypofunction and cognitive enhancement.
    Gregory KJ; Herman EJ; Ramsey AJ; Hammond AS; Byun NE; Stauffer SR; Manka JT; Jadhav S; Bridges TM; Weaver CD; Niswender CM; Steckler T; Drinkenburg WH; Ahnaou A; Lavreysen H; Macdonald GJ; Bartolomé JM; Mackie C; Hrupka BJ; Caron MG; Daigle TL; Lindsley CW; Conn PJ; Jones CK
    J Pharmacol Exp Ther; 2013 Nov; 347(2):438-57. PubMed ID: 23965381
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention.
    Gomes FV; Grace AA
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.